inclusion criteria: pregnant (positive β-human chorionic gonadotropin test, β-hcg) or lactating female at screening. patients with a history of retinopathy, sickle cell disease or trait, psoriasis, porphyria, history of splenectomy, mental illness or uncontrolled seizures disorder, known active tuberculosis or history of incompletely treated tuberculosis, patients on chronic immunosuppression for other medical conditions such as rheumatological disorders, inflammatory bowel disease, or in patients with organ transplants. patients admitted in icu. taking medications which may lead to interactions with hydroxychloroquine, including penicillamine, telbivudine, botulinum toxin, fluconazole, digoxin, propafenone , cimetidine, statins, warfarin, and cyclosporine within 2 weeks of dosing start, and during the duration of the study. history of glucose-6-phosphate dehydrogenase deficiency. pre-treatment corrected qt interval (qtc) ≥450 milliseconds.

inclusion criteria: pregnant (positive β-human chorionic gonadotropin test, β-hcg) or lactating female at screening. patients with a history of retinopathy, sickle cell disease or trait, psoriasis, porphyria, history of splenectomy, mental illness or uncontrolled seizures disorder, known active tuberculosis or history of incompletely treated tuberculosis, patients on chronic immunosuppression for other medical conditions such as rheumatological disorders, inflammatory bowel disease, or in patients with organ transplants. patients admitted in icu. taking medications which may lead to interactions with hydroxychloroquine, including penicillamine, telbivudine, botulinum toxin, fluconazole, digoxin, propafenone , cimetidine, statins, warfarin, and cyclosporine within 2 weeks of dosing start, and during the duration of the study. history of glucose-6-phosphate dehydrogenase deficiency. pre-treatment corrected qt interval (qtc) ≥450 milliseconds.

inclusion criteria: 1. pregnant (positive β-human chorionic gonadotropin test, β-hcg) or lactating female at screening. 2. patients with a history of retinopathy, sickle cell disease or trait, psoriasis, porphyria, history of splenectomy, mental illness or uncontrolled seizures disorder, known active tuberculosis or history of incompletely treated tuberculosis, patients on chronic immunosuppression for other medical conditions such as rheumatological disorders, inflammatory bowel disease, or in patients with organ transplants. 3. patients admitted in icu. 4. taking medications which may lead to interactions with hydroxychloroquine, including penicillamine, telbivudine, botulinum toxin, fluconazole, digoxin, propafenone , cimetidine, statins, warfarin, and cyclosporine within 2 weeks of dosing start, and during the duration of the study. 5. history of glucose-6-phosphate dehydrogenase deficiency. 6. pre-treatment corrected qt interval (qtc) ≥450 milliseconds.

inclusion criteria: 1. pregnant (positive β-human chorionic gonadotropin test, β-hcg) or lactating female at screening. 2. patients with a history of retinopathy, sickle cell disease or trait, psoriasis, porphyria, history of splenectomy, mental illness or uncontrolled seizures disorder, known active tuberculosis or history of incompletely treated tuberculosis, patients on chronic immunosuppression for other medical conditions such as rheumatological disorders, inflammatory bowel disease, or in patients with organ transplants. 3. patients admitted in icu. 4. taking medications which may lead to interactions with hydroxychloroquine, including penicillamine, telbivudine, botulinum toxin, fluconazole, digoxin, propafenone , cimetidine, statins, warfarin, and cyclosporine within 2 weeks of dosing start, and during the duration of the study. 5. history of glucose-6-phosphate dehydrogenase deficiency. 6. pre-treatment corrected qt interval (qtc) ≥450 milliseconds.